The present invention provides novel artificial tears containing a recombinant human lysozyme and a recombinant human epidermal growth factor. The novel artificial tears comprise main components and an auxiliary material. The main components are a recombinant human lysozyme, a recombinant human epidermal growth factor, and sodium hyaluronate, wherein the recombinant human lysozyme, the recombinant human epidermal growth factor, and sodium hyaluronate are contained in an amount from 0.075 % to 0.30 %, from 0.002% to 0.004%, and from 0.10% to 0.30% respectively in the total mass of the novel artificial tears.
